We showed in the TRAMP-C2 murine syngeneic tumor model that treatment with either an agonistic anti-CD40 antibody alone or IL-15 prolonged animal survival, however the combination of agonistic anti-CD40 with IL-15 produced markedly additive effects when compared with either agent alone (68). This evidence concerns the gene CD40 and neoplasm.